Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study

Table 2 Significant correlations between serum biomarkers and Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Disease Activity Index, and ankylosing spondylitis spine magnetic resonance imaging score for activity changes among golimumab-treated patients

Serum biomarker, time, number of golimumab-treated patients	Spearman correlation coefficient (r _s); Bonferroni-adjusted p-value with respective outcome
	Change in ASDAS from baseline to week 104
Leptin
Baseline, n = 58	0.55; 0.040
	Change in BASDAI from baseline to week 14
C3
Change from baseline to week 4, n = 76	0.55; 0.001
Change from baseline to week 14, n = 76	0.49; 0.040
	Change in ASspiMRI-a score from baseline to week 14
IL-6
Baseline, n = 48	−0.63; 0.009
Change from baseline to week 4, n = 48	0.61; 0.022
Change from baseline to week 14, n = 48	0.59; 0.043
TIMP-1
Baseline, n = 35	−0.67; 0.044
C3
Change from baseline to week 4, n = 35	0.72; 0.005

Abbreviations: ASDAS Ankylosing Spondylitis Disease Activity Score employing C-reactive protein, ASspiMRI-a Ankylosing spondylitis spine magnetic resonance imaging score for activity, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, C3 Complement component 3, IL Interleukin, TIMP-1 Tissue inhibitor of metalloproteinase-1

ISSN: 1478-6362